Trial Profile
Immunogenicity and Safety Study of GSK Biologicals' Trivalent Split Virion Influenza Vaccine (GSK1536489A) Fluviral® (2012/2013 Season) in Adults Aged 18 Years and Older
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Dec 2023
Price :
$35
*
At a glance
- Drugs GSK 1536489A (Primary)
- Indications Influenza virus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 24 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Aug 2012 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Jun 2012 New trial record